BIOCELTIX S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66 PLN | +1.69% |
|
-4.07% | -26.67% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 171.6 | 133 | 371.7 |
| Enterprise Value (EV) 1 | 166 | 129.2 | 362.5 |
| P/E ratio | -37.5 x | -14.5 x | -25.8 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -41.2 x | -15.2 x | -26.7 x |
| EV / FCF | - | -20,292,503 x | -40,767,506 x |
| FCF Yield | - | -0% | -0% |
| Price to Book | 28.6 x | 25.8 x | 35.5 x |
| Nbr of stocks (in thousands) | 3,287 | 3,427 | 4,129 |
| Reference price 2 | 52.20 | 38.80 | 90.00 |
| Announcement Date | 5/2/23 | 5/2/23 | 4/26/24 |
1PLN in Million2PLN
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales | - | - | - |
| EBITDA 1 | -4.027 | -8.51 | -13.58 |
| EBIT 1 | -4.404 | -8.955 | -14.02 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | -4.356 | -8.967 | -13.69 |
| Net income 1 | -4.398 | -8.921 | -13.69 |
| Net margin | - | - | - |
| EPS 2 | -1.391 | -2.674 | -3.493 |
| Free Cash Flow | - | -6.365 | -8.892 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 5/2/23 | 5/2/23 | 4/26/24 |
1PLN in Million2PLN
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | 5.52 | 3.83 | 9.14 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | -6.36 | -8.89 |
| ROE (net income / shareholders' equity) | - | -160% | -175% |
| ROA (Net income/ Total Assets) | - | -70.6% | -85.9% |
| Assets 1 | - | 12.63 | 15.93 |
| Book Value Per Share 2 | 1.820 | 1.500 | 2.530 |
| Cash Flow per Share 2 | 1.840 | 1.200 | 2.250 |
| Capex 1 | 0.01 | 0.35 | 0.46 |
| Capex / Sales | - | - | - |
| Announcement Date | 5/2/23 | 5/2/23 | 4/26/24 |
1PLN in Million2PLN
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -26.67% | 69.16M | |
| -14.09% | 77.37B | |
| +18.66% | 8.74B | |
| +23.75% | 3.67B | |
| -0.42% | 3.25B | |
| +18.07% | 1.73B | |
| -16.99% | 1.38B | |
| -26.05% | 1.24B | |
| -17.86% | 1.07B | |
| -6.77% | 976M |
- Stock Market
- Equities
- BCX Stock
- Financials Bioceltix S.A.
